Jeremy Magalon1, Olivier Bausset2, Nicolas Serratrice2, Laurent Giraudo2, Houssein Aboudou2, Julie Veran2, Guy Magalon2, Françoise Dignat-Georges3, Florence Sabatier4. 1. Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, Aix-Marseille University, Marseille, France. Electronic address: jeremy.magalon@nck.aphp.fr. 2. Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, Aix-Marseille University, Marseille, France. 3. Hematology Laboratory, Hôpital de la Conception, AP-HM, Aix-Marseille University, Marseille, France. 4. Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, Aix-Marseille University, Marseille, France; Hematology Laboratory, Hôpital de la Conception, AP-HM, Aix-Marseille University, Marseille, France.
Abstract
PURPOSE: The purpose of this study was to compare the biological characteristics of platelet-rich plasma (PRP) obtained from 4 medical devices and a preparation developed in our laboratory using a single-donor model. METHODS: Ten healthy persons donated blood that was processed to produce PRP by use of 4 commercial preparation systems and a protocol developed in our laboratory. Volumes and platelet, white blood cell (WBC), and red blood cell concentrations were recorded. The platelet activation status was assessed by flow cytometry. Enzyme-linked immunosorbent assay was used to determine the concentrations of vascular endothelial growth factor, platelet-derived growth factor AB, epidermal growth factor, and transforming growth factor β1. We calculated platelet capture efficiency, relative composition, and increase factors from whole blood in platelets and WBC, as well as platelet and growth factor (GF) doses, provided from each preparation. RESULTS: Leukocyte-rich PRP was obtained with RegenPRP (RegenLab, Le Mont-sur-Lausanne, Switzerland) and the Mini GPS III System (Biomet Biology, Warsaw, IN) and provides PRP with higher proportions of red blood cells, WBCs, and neutrophils than leukocyte-poor PRP obtained with the Selphyl System (Selphyl, Bethlehem, PA), Arthrex ACP (Arthrex, Naples, FL), and the preparation developed in our laboratory. The highest platelet and GF concentrations and doses were obtained with the Mini GPS III System and the preparation developed in our laboratory. Different centrifugation protocols did not show differences in the percentages of activated platelets. Finally, a positive correlation between platelet doses and all the GFs studied was found, whereas a positive correlation between WBC doses and GFs was found only for vascular endothelial growth factor and epidermal growth factor. CONCLUSIONS: In a single-donor model, significant biological variations in PRP obtained from different preparation systems were highlighted. The observed differences suggest different results for treated tissue and could explain the large variability in the clinical benefit of PRP reported in the literature. CLINICAL RELEVANCE: Our findings will help clinicians to choose a system that meets their specific needs for a given indication.
PURPOSE: The purpose of this study was to compare the biological characteristics of platelet-rich plasma (PRP) obtained from 4 medical devices and a preparation developed in our laboratory using a single-donor model. METHODS: Ten healthy persons donated blood that was processed to produce PRP by use of 4 commercial preparation systems and a protocol developed in our laboratory. Volumes and platelet, white blood cell (WBC), and red blood cell concentrations were recorded. The platelet activation status was assessed by flow cytometry. Enzyme-linked immunosorbent assay was used to determine the concentrations of vascular endothelial growth factor, platelet-derived growth factor AB, epidermal growth factor, and transforming growth factor β1. We calculated platelet capture efficiency, relative composition, and increase factors from whole blood in platelets and WBC, as well as platelet and growth factor (GF) doses, provided from each preparation. RESULTS: Leukocyte-rich PRP was obtained with RegenPRP (RegenLab, Le Mont-sur-Lausanne, Switzerland) and the Mini GPS III System (Biomet Biology, Warsaw, IN) and provides PRP with higher proportions of red blood cells, WBCs, and neutrophils than leukocyte-poor PRP obtained with the Selphyl System (Selphyl, Bethlehem, PA), Arthrex ACP (Arthrex, Naples, FL), and the preparation developed in our laboratory. The highest platelet and GF concentrations and doses were obtained with the Mini GPS III System and the preparation developed in our laboratory. Different centrifugation protocols did not show differences in the percentages of activated platelets. Finally, a positive correlation between platelet doses and all the GFs studied was found, whereas a positive correlation between WBC doses and GFs was found only for vascular endothelial growth factor and epidermal growth factor. CONCLUSIONS: In a single-donor model, significant biological variations in PRP obtained from different preparation systems were highlighted. The observed differences suggest different results for treated tissue and could explain the large variability in the clinical benefit of PRP reported in the literature. CLINICAL RELEVANCE: Our findings will help clinicians to choose a system that meets their specific needs for a given indication.
Authors: Jagoda M Jalowiec; Matteo D'Este; Jennifer Jane Bara; Jessica Denom; Ursula Menzel; Mauro Alini; Sophie Verrier; Marietta Herrmann Journal: Tissue Eng Part C Methods Date: 2015-12-01 Impact factor: 3.056
Authors: Wenhai Zhang; Yue Guo; Mitchell Kuss; Wen Shi; Amy L Aldrich; Jason Untrauer; Tammy Kielian; Bin Duan Journal: Tissue Eng Part B Rev Date: 2019-05-15 Impact factor: 6.389
Authors: Andreas Voss; Mary Beth McCarthy; Donald Allen; Mark P Cote; Knut Beitzel; Andreas B Imhoff; Augustus D Mazzocca Journal: Arthrosc Tech Date: 2016-05-02
Authors: Marcus Vinicius Danieli; João Paulo Fernandes Guerreiro; Alexandre Oliveira Queiroz; Hamilton da Rosa Pereira; Daniele Cristina Cataneo Journal: Int Orthop Date: 2020-09-29 Impact factor: 3.075